I've been reading Novo patents for crystal sizes. The most
promising US patent is #2799622: "Process of Producing
Insulin Crystals of Substantially Uniform Size and
Compositions Thereof," 16 July, 1957.
This patent provides an equation to estimate seed crystal
requirements given seed crystal size, required finished
crystal size and weight of insulin that will be crystalized.
The examples focus on 30 micron required finished size and
states it is possible to obtain 80-90% in the form of 28-36
micron crystals. This diameter is the longest diagonal
distance across the crystals. Assuming a normal (Gaussian)
distribution, setting the mean to 32 microns and forcing the
difference of integrals:
int(28,infinity) - int(36, infinity) = 0.85 or 85% yield
This gives a standard deviation of 2.75 microns in crystal
size. So the mean+2SD=~37.5 or about 38 microns for the
maximum crystal size in commercial ultralente. The lower
size is probably 26 microns.
This assumes a perfect seed size of 4 microns as recommended
in the patent. If the manufacturer is sloppy then the sizes
could be less uniform.
In any case, this is very close to Michel's 40 micron
number.
This range of crystal sizes in ultralente could cause
variable subcutaneous absorption characteristics. It also
suggests there could be differences in crystal sizes between
batches from the manufacturer (only Lilly these days).
Novo patent US#2882202: "Insulin Crystal Preparations and
Methods of Producting Them," 14 April, 1959; states 10
micron crystals produce the same basal insulinemia effect
(time course of action) as amorphous PZI in dog models.
Crystal sizes of 25-100 microns have longer effects than PZI
in dog models. This is an excellent benchmark to keep in
mind as it probably set the goal for the 30 micron design
size above.
Food for thought,
--
Jim Dumas T1 4/86, background retinopathy, rarely
hypoglycemic: <1/mo. lispro+R+U+NPH daily, moderate
exercise, typically <6% HbA1c